Innolake Biopharm
PrivateLast Round
Series A
Extension
Jun 5, 2023
Total Funding Raised
$53.99M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Innolake Biopharm operates in Healthcare & Life Sciences and is based in Hangzhou. Its latest recorded funding round was a Series A Extension round in June 2023.
Innolake Biopharm is a clinical-stage biotechnology company that develops therapeutic drugs for cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Innolake Biopharm Comparables
Compare Innolake Biopharm with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MediLink Therapeutics | 88% | |
| Minghui Pharmaceutical | 86% | |
| Duality Biotherapeutics Inc | 85% |
For institutional investors. Book with your work email.
Innolake Biopharm Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Jun 5, 2023 | ||||
| Early Funding | Apr 6, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Innolake Biopharm Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Zhongbo Juli | Series A Extension |
| Hangzhou Heda Industry Fund | Series A Extension |
| Huagai Capital | Early Funding |
| CDH Investments | Early Funding |
| Zhongbo Venture Capital | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 11, 2026
Monthly visitors increased 78% MoM.
- Jun 5, 2023
$14M round led by Zhongbo Juli and Hangzhou Heda Industry Fund.
For institutional investors. Book with your work email.
Innolake Biopharm Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Innolake Biopharm's valuation, stock price, and market status.
Is Innolake Biopharm a public or private company?
Innolake Biopharm is a private company.
What is the current stock price of Innolake Biopharm?
Innolake Biopharm is a private company, so its shares have no public market price. Caplight tracks Innolake Biopharm's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Innolake Biopharm worth (valuation)?
Valuation information for Innolake Biopharm is not publicly available.
Can I buy Innolake Biopharm stock?
Innolake Biopharm shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Innolake Biopharm's last funding round?
Innolake Biopharm's most recent funding round was Series A Extension on June 5, 2023.
Who are the main investors in Innolake Biopharm?
Key investors in Innolake Biopharm include Zhongbo Juli, Hangzhou Heda Industry Fund, Zhongbo Venture Capital.
Will Innolake Biopharm IPO soon?
No public IPO plans have been announced for Innolake Biopharm.
How can I track Innolake Biopharm secondary market activity?
Caplight tracks bids, offers, and trades in Innolake Biopharm's shares on secondary markets.